Search Bar & Filters
Found 2 Actively Recruiting clinical trials
Actively Recruiting
Researchers are conducting a national, prospective, multicenter, non-interventional pilot project to screen for Hepatitis C virus HCV infection among people who inject drugs PWID in the Czech Republic. The main goal is to prepare, implement, and assess a method for early detection of Hepatitis C and to develop new procedures for integrating this screening into social health care systems. This project aims to help prevent further transmission of the virus by improving early diagnosis and care continuity.
Actively Recruiting
Researchers are evaluating maridebart cafraglutide as an additional treatment to standard care to reduce heart failure events, cardiovascular deaths, and improve symptoms in adults with heart failure who have preserved or mildly reduced ejection fraction and obesity. This phase 3 global trial includes a double-blind period followed by an open-label extension. The study will continue until approximately 850 primary endpoint events have occurred, focusing on serious heart failure outcomes. Participants will be randomly assigned to receive either maridebart cafraglutide or a placebo, both given by subcutaneous injection. The trial includes two parts an initial double-blind phase where neither participants nor researchers know the assigned treatment, followed by an open-label extension where all participants may receive the active drug. This design helps assess the drugs impact on heart failure and related cardiovascular events. During the study, participants will undergo regular assessments including questionnaires to measure heart failure symptoms and quality of life, blood tests for kidney function, blood sugar, cholesterol, and inflammation markers, as well as monitoring of heart failure events and mortality. The main outcome is the time until cardiovascular death or heart failure events over about 35 months. Safety and other health measures will also be tracked throughout the trial, which lasts up to about three years.